CRIS
CURIS INC
NASDAQ · Healthcare · Biotechnology · US
$0.40
+4.72%Oct 16, 2026, 12:00 UTC
Curis entered into securities purchase agreements with existing healthcare-focused institutional investors for a private placement of 16,666,680 common shares or pre-funded warrants, plus warrants to purchase up to 16,666,680 shares, at an effective combined price of $0.51 per share or pre-funded warrant and accompanying warrant.
Source:Aug 13, 2026, 12:00 UTC
Curis, Inc. priced a public offering of 3,733,334 shares of common stock (or pre-funded warrants) and warrants to purchase up to 3,733,334 shares of common stock at a combined price of $1.50 per share and accompanying warrant, raising approximately $5.6 million from healthcare-focused institutional investors.
Source:Jul 30, 2026, 12:00 UTC
Curis dosed the first five patients in its TakeAim CLL study for emavusertib in patients with Chronic Lymphocytic Leukemia.
Source:Jul 22, 2026, 17:04 UTC
Curis Inc. announced updated positive clinical trial results for its investigational drug emavusertib and expanded trial timeline guidance.
Source: